Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|February 8, 2020
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 casesGuillaume Aussedat, Alexandra Traverse-Glehen, Aspasia Stamatoullas, et al.
Haematologica|February 2, 2023
Somatic genetic alterations predict hematological progression in GATA2 deficiencyLaetitia Largeaud, Matthew Collin, Nils Monselet, et al.
Hemasphere|April 10, 2026
Erdheim-Chester disease associated with myeloid neoplasm: Clinical features, molecular landscape, and treatment outcomesAmbroise Le Pogam, Matthias Papo, Pierre Hirsch, et al.
Leukemia|June 26, 2020
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapyMarco Cerrano, Matthieu Duchmann, Rathana Kim, et al.
Journal of Cellular and Molecular Medicine|September 7, 2021
Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomesVincent Parinet, Elise Chapiro, Audrey Bidet, et al.
Nature Communications|November 4, 2022
JAK2V617F mutation drives vascular resident macrophages toward a pathogenic phenotype and promotes dissecting aortic aneurysmRida Al-Rifai, Marie Vandestienne, Jean-Rémi Lavillegrand, et al.
The Journal of Experimental Medicine|March 9, 2016
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemiaHéléna Boutzen, Estelle Saland, Clément Larrue, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
RMD Open|July 22, 2022
Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patientsMohamed-Yacine Khitri, Alexis F Guedon, Sophie Georgin-Lavialle, et al.
Leukemia|March 27, 2026
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemiaLoïc Vasseur, Matthieu Duchmann, Nicolas Duployez, et al.
Pageof 6